End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.55 USD | -3.53% | -13.93% | -73.04% |
May. 14 | Transcript : The Oncology Institute, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (TOI) TOI MANAGEMENT LLC Reports Q1 Revenue $94.7M, vs. Street Est of $95.2M | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-73.04% | 40.94M | - | - | |
+17.74% | 82.59B | C+ | ||
-29.66% | 69.86B | B- | ||
0.00% | 26.5B | C+ | ||
+3.06% | 17.29B | A- | ||
-12.16% | 16.61B | B | ||
+2.47% | 15.56B | A- | ||
+74.82% | 13.2B | C- | ||
+0.76% | 12.75B | B- | ||
+73.52% | 12.6B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- TOI Stock
- Ratings The Oncology Institute, Inc.